NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Diagnostics & Research · USD

Quest Diagnostics Incorporated (DGX) Stock Analysis

Quest Diagnostics Incorporated (DGX) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

DGX

$238.93

+$1.81 (+0.76%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DGX with… →

DGX Key Statistics

As of Oct 21, 2026
Trading
Open
$235.34
Previous Close
$237.12
Day's Range
223.50–240.54
52-Week Range
171.18–248.84
Volume
1.21M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.54
Valuation
Market Cap
$26.37B
P/E Ratio
25.36
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
19.85
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.54
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.28
EPS (ttm)Profit attributable to each share over the last twelve months.
9.42
Financials (FY)
Revenue (FY)
$11.04B+11.78%
Net Income (FY)
$992.00M+13.89%
Profit marginThe share of revenue left as profit after all costs and taxes.
9.19%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
110.37M
1-Year Return
+31.58%
Dividend and dates
Dividend
$3.44+1.45%
Ex-Dividend Date
October 6, 2026
Earnings Date
October 22, 2026
Avg Volume
1.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DGX closed at $238.93, +31.58% over 1 year.

Quest Diagnostics Incorporated (DGX) has a market capitalization of $26.37B.

In fiscal 2025, DGX reported revenue of $11.04B.

DGX Stock Return by Calendar Year

Quest Diagnostics Incorporated (DGX) 10-year return: what $10,000 became

1 year
$10,000 $13,158
+31.58%
5 years
$10,000 $18,104
+81.04%
10 years
$10,000 $34,753
+247.53%

If you had invested $10,000 in Quest Diagnostics Incorporated (DGX) 10 years ago, at the close on October 21, 2016, it would have been worth $34,753 at the close on October 21, 2026: +247.53% in total, +13.27% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+40.00%
2025+17.20%
2024+11.77%
2023−10.05%
2022−7.80%
2021+47.86%
2020+14.11%
2019+31.13%
2018−13.84%
2017+9.16%
2016 (partial year)+8.32%

As of October 21, 2026.

DGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$11.04B$992.00M9.0%
2024$9.87B$871.00M8.8%
2023$9.25B$854.00M9.2%
2022$9.88B$946.00M9.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$11.04B$3.67B$1.56B$992.00M9.0%
2024$9.87B$3.24B$1.35B$871.00M8.8%
2023$9.25B$3.05B$1.26B$854.00M9.2%
2022$9.88B$3.43B$1.43B$946.00M9.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DGX Dividend History

$3.15+6.4% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$3.384—
2025$3.154+6.4%
2024$2.964+6.1%
2023$2.794+7.3%
YearDividends per sharePaymentsChange
2026 (partial year)$3.384—
2025$3.154+6.4%
2024$2.964+6.1%
2023$2.794+7.3%
2022$2.604+7.4%
2021$2.424+9.5%
2020$2.214+4.2%
2019$2.124+8.7%
2018$1.954+8.3%
2017$1.804—

Most recent payment: $0.85 per share, ex-dividend October 6, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

DGX Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricDGXDiagnostics & Research medianvs median
P/E25.3637.5933% below
P/S ratio2.285.2356% below
Profit margin9.19%−0.93%10.1 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Quest Diagnostics Incorporated (DGX) carries a market capitalisation of $26.37B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 46,000.

The 52-week range on file runs from $171.18 to $248.84. The most recent close on file for DGX is $238.93, dated October 21, 2026. That is +$1.81 (+0.76%) against the previous close. The latest close sits 39.58% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $11.04B. Against the prior fiscal year total of $9.87B, that is a change of +11.78%. The same year closed with net income of $992.00M. That is +13.89% against the prior fiscal year. The reported profit margin is 9.19%. That is 10.1 percentage points above the Diagnostics & Research median of −0.93%. Earnings per share on a trailing basis come to 9.42.

Across the 4 fiscal years on file, revenue moves from $9.88B in 2022 to $11.04B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

DGX trades at a trailing price-to-earnings ratio of 25.36. That is 32.53% below the Diagnostics & Research median of 37.59. On forward earnings the ratio is 19.85. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.54. Measured against sales, the shares trade at 2.28 times revenue. On price-to-sales that is 56.36% below the Diagnostics & Research median of 5.23. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +31.58%. Across 10 years the annualized return works out at +13.27%. Beta against the wider market is reported at 0.54. Annualized volatility over the trailing 10 years is 24.07%.

Growth & Income

DGX pays a dividend yielding 1.45%. That is 0.7 percentage points above the Diagnostics & Research median yield of 0.71%. The indicated annual rate is $3.44 a share. The ex-dividend date on file is October 6, 2026. Dividends are recorded for 10 calendar years; 2026 shows 4 payments totalling $3.38 a share. The year before, 2025, totalled $3.15 a share.

Across the complete calendar years on file, 2021 returned +47.86% and 2018 returned −13.84%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the total return is +40.00%.

Peer Comparison

Quest Diagnostics Incorporated (DGX) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Quest Diagnostics Incorporated DGX $26.37B 25.4
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. Quest Diagnostics Incorporated trades at a P/E of 25.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Visit website →